Triple therapy prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT)

三联疗法预防复发性脑内疾病事件试验 (TRIDENT)

• 批准号: nhmrc : GNT1103886
• 负责人: Dr Shoichiro Sato
• 金额: $ 525.63万
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2016
• 资助国家: 澳大利亚
• 起止时间: 2016-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/triple-therapy-prevention-trial-trident/1346312
• 关键词: Triple; therapy; prevention; Recurrent; Intracerebral

Acute intracerebral haemorrhage (ICH) is a serious form of stroke. Survivors of ICH are at high risk of repeat events. Blood pressure lowering is a very important to prevent repeat events but data shows blood pressure is poorly controlled in these patients. In this research we investigate whether an approach that uses a 'triple pill' strategy (3 low dose BP drugs in one pill) in ICH patients with mild to moderate hypertension can decrease major cardiovascular events.

急性脑出血(ICH)是一种严重的中风。脑出血的幸存者有很高的复发风险。降低血压对防止复发非常重要，但数据显示，这些患者的血压控制不佳。在这项研究中，我们调查了在患有轻中度高血压的脑出血患者中使用“三粒药”策略(一粒药中有3种低剂量的BP药物)是否可以减少主要的心血管事件。